Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Vaccinations01:51

Vaccinations

54.6K
Overview
54.6K
Development of Human Microbiota01:30

Development of Human Microbiota

44
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
44
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

41
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
41
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.4K
Active versus Passive Immunity01:31

Active versus Passive Immunity

12.2K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
12.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

Human vaccines & immunotherapeutics·2026
Same author

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

The lancet. HIV·2025
Same author

Public priorities for primary care in Canada: Report on insights and actionable recommendations from 5 provincial reference panels.

Canadian family physician Medecin de famille canadien·2025
Same author

Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm.

Vaccine·2024
Same author

Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.

Vaccine·2024
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Published on: July 31, 2021

4.3K

Determinants of maternal immunization in developing countries.

Jayani Pathirana1, Jerome Nkambule2, Steven Black3

  • 1P.O. Box 51590, Limbe, Malawi.

Vaccine
|May 5, 2015
PubMed
Summary
This summary is machine-generated.

Maternal tetanus toxoid vaccination protects infants, but barriers exist in developing countries. Addressing health system, provider, and patient factors is crucial for improving immunization coverage and reducing neonatal mortality.

Keywords:
Antenatal careBarriersMaternal immunizationNewbornTetanus

More Related Videos

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
08:12

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Published on: September 6, 2019

7.7K
Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
09:57

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay

Published on: August 6, 2020

6.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Published on: July 31, 2021

4.3K
Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
08:12

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Published on: September 6, 2019

7.7K
Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
09:57

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay

Published on: August 6, 2020

6.9K

Area of Science:

  • Public Health
  • Immunology
  • Global Health

Background:

  • Maternal immunization protects infants with immature immune responses.
  • Tetanus toxoid vaccination in pregnant women is vital in high-neonatal mortality regions.
  • Identifying barriers to maternal tetanus vaccination is key to improving immunization platforms.

Purpose of the Study:

  • To identify barriers to maternal tetanus vaccination in developing African and Asian countries.
  • To inform strategies for enhancing maternal immunization programs.

Main Methods:

  • Categorized barriers into health system, health care provider, and patient factors.
  • Conducted a literature review on identified barrier categories.
  • Performed a pilot survey of healthcare providers in Malawi regarding immunization barriers.

Main Results:

  • Health system barriers include inadequate resources and poor logistics.
  • Healthcare provider barriers involve low Antenatal Care attendance and knowledge gaps.
  • Patient barriers stem from lack of education, socioeconomic factors, and high parity.

Conclusions:

  • Improving maternal tetanus immunization requires addressing provider and patient knowledge, Antenatal Care attendance, and outreach.
  • Strengthening health systems and immunization services is essential.
  • Further analysis is needed to refine maternal immunization strategies and delivery systems.